- Starpharma has received another regulatory approval for its VivaGel BV product in Asia
- VivaGel BV, which targets treatment and prevention of bacterial vaginosis, has been licensed in 160 countries
- Starpharma’s share price is down 3.04 per cent today, currently sitting at $1.12 apiece
Pharmaceutical company Starpharma is continuing to improve its presence in Asia after receiving another regulatory approval in the continent.
The company, which focuses on women’s health through its VivaGel line, secured another approval for the product in Asia through its supplier, Mundipharma.
Starpharma’s CEO Dr Jackie Fairley said the companies are impressed by the “momentum” achieved in receiving approvals.
“We are very pleased to achieve momentum with these approvals for VivaGel BV in Asia,” she said.
“We are working closely with Mundipharma to achieve approvals throughout the region and look forward to providing this breakthrough product for BV to patients in Asia.”
Mundipharma owns pharmaceutical companies internationally, and operates in 12 countries throughout Asia and includes China, Indonesia and Japan.
The companies are releasing VivaGel BV under the name BETADINE BV Gel throughout Asia, in the coming months.
For now, the two pharmaceutical businesses aren’t disclosing which Asian countries have given regulatory approval, for competitive reasons.
Starpharma and Mundipharama are continuing to apply for more regulatory approvals throughout Asia and internationally.
So far, VivaGel BV, which targets treatment and prevention of bacterial vaginosis, has been licensed in 160 countries.
It is an antiviral and blocks bacteria, and several clinical studies have successfully proved VivaGel to be both safe and effective.
According to Starpharma, one in three women will experience bacterial vaginosis, being the most common vaginal condition worldwide.
Starpharma’s share price is down 3.04 per cent today, currently sitting at $1.12 apiece, as of AEST 1:01 pm.